Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. (Q40416131)

20 September 2017

Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. (English)

1 reference

20 September 2017

0 references

8

David Montefiori

1 reference

20 September 2017

Ethan Poteet

1

1 reference

20 September 2017

Phoebe Lewis

2

1 reference

20 September 2017

Changyi Chen

3

1 reference

20 September 2017

Sam On Ho

4

1 reference

20 September 2017

Thai Do

5

1 reference

20 September 2017

SuMing Chiang

6

1 reference

20 September 2017

Celia Labranche

7

1 reference

20 September 2017

Gary Fujii

9

1 reference

20 September 2017

Qizhi Yao

10

1 reference

20 September 2017

language of work or name

English

0 references

publication date

27 October 2016

1 reference

20 September 2017

1 reference

20 September 2017

34

1 reference

20 September 2017

48

1 reference

20 September 2017

5886-5894

1 reference

Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine.

20 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Production and characterization of simian--human immunodeficiency virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Human immunodeficiency virus-like particles activate multiple types of immune cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Virus-like particle vaccine activates conventional B2 cells and promotes B cell differentiation to IgG2a producing plasma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

A Novel Prime and Boost Regimen of HIV Virus-Like Particles with TLR4 Adjuvant MPLA Induces Th1 Oriented Immune Responses against HIV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Toll-like receptors as adjuvant receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

TLR-based immune adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

HIV Gag protein conjugated to a Toll-like receptor 7/8 agonist improves the magnitude and quality of Th1 and CD8+ T cell responses in nonhuman primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Effects of adjuvants on IgG subclasses elicited by virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Biology of germinal centers in lymphoid tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Maturation of the immune response in germinal centers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

T follicular helper cells express a distinctive transcriptional profile, reflecting their role as non-Th1/Th2 effector cells that provide help for B cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Murine immunosuppression with mycoviral dsRNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Measuring HIV neutralization in a luciferase reporter gene assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Divergent immunoglobulin g subclass activity through selective Fc receptor binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Unresponsiveness of MyD88-deficient mice to endotoxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Persistent antigen and germinal center B cells sustain T follicular helper cell responses and phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Development of the expressed Ig CDR-H3 repertoire is marked by focusing of constraints in length, amino acid use, and charge that are first established in early B cell progenitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

The use of a TLR2 agonist-based adjuvant for enhancing effector and memory CD8 T-cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

Role of Toll-like receptors in costimulating cytotoxic T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2016.10.036

10.1016/J.VACCINE.2016.10.036

7 January 2021

Identifiers

DOI

1 reference

20 September 2017

1 reference